The accumulation of amyloid-β (Aβ) peptides is a hallmark of Alzheimer's disease (AD). Central to AD pathology is the production of Aβ peptides through the amyloidogenic processing of amyloid-β protein precursor (AβPP) by β-secretase (BACE-1) and γ-secretase. Recent studies have shifted focus from Aβ plaque deposits to the more toxic soluble Aβ oligomers. One significant way in which Aβ peptides impair neuronal information processing is by influencing neurotransmitter receptor function. These receptors, including adrenergic, acetylcholine, dopamine, 5-HT, glutamate, and gamma-aminobutyric acid (GABA) receptors, play a crucial role in regulating synaptic transmission, which underlies perceptual and cognitive functions. This review explores how Aβ interacts with these key neurotransmitter receptors and how these interactions contribute to neural dysfunction in AD. Moreover, we examine how agonists and antagonists of these receptors influence Aβ pathology, offering new perspectives on potential therapeutic strategies to curb AD progression effectively and improve patients’ quality of life.
ZhaoJLiuXXiaW, et al.Targeting amyloidogenic processing of APP in Alzheimer's disease. Front Mol Neurosci2020; 13: 137.
2.
AndersonJPEschFSKeimPS, et al.Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci Lett1991; 128: 126–128.
3.
WilsonCADomsRWLeeVM. Intracellular APP processing and aβ production in Alzheimer disease. J Neuropathol Exp Neurol1999; 58: 787–794.
4.
BurdickDSoreghanBKwonM, et al.Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem1992; 267: 546–554.
5.
SherringtonRRogaevELiangY, et al.Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature1995; 375: 754–760.
6.
De JongheCEsselensCKumar-SinghS, et al.Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability. Hum Mol Genet2001; 10: 1665–1671.
7.
ChenWGamacheERosenmanDJ, et al.Familial Alzheimer’s mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat Commun2014; 5: 3037.
8.
LambertMPBarlowAChromyBA, et al.Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A1998; 95: 6448–6453.
9.
KayedRHeadEThompsonJL, et al.Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science2003; 300: 486–489.
10.
WalshDMKlyubinIFadeevaJV, et al.Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature2002; 416: 535–539.
11.
WilcoxKCLacorPNPittJ, et al.Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol2011; 31: 939–948.
12.
TomiyamaTMatsuyamaSIsoH, et al.A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci2010; 30: 4845–4856.
13.
WeissEKannMWangQ. Neuromodulation of neural oscillations in health and disease. Biology (Basel)2023; 12: 371.
14.
SabatiniBLTianL. Imaging neurotransmitter and neuromodulator dynamics in vivo with genetically encoded indicators. Neuron2020; 108: 17–32.
15.
McCormickDAWangZHuguenardJ. Neurotransmitter control of neocortical neuronal activity and excitability. Cereb Cortex1993; 3: 387–398.
16.
DelisIDmochowskiJPSajdaP, et al.Correlation of neural activity with behavioral kinematics reveals distinct sensory encoding and evidence accumulation processes during active tactile sensing. NeuroImage2018; 175: 12–21.
17.
ZhengHJVWangQStanleyGB. Adaptive shaping of cortical response selectivity in the vibrissa pathway. J Neurophysiol2015; 113: 3850–3865.
18.
SharmaKPradhanSDuffyLK, et al.Role of receptors in relation to plaques and tangles in Alzheimer's disease pathology. Int J Mol Sci2021; 22: 12987.
19.
ZhaoJDengYJiangZ, et al.G protein-coupled receptors (GPCRs) in Alzheimer’s disease: a focus on BACE1 related GPCRs. Front Aging Neurosci2016; 8: 58.
20.
ClewettDHuangRVelascoR, et al.Locus coeruleus activity strengthens prioritized memories under arousal. J Neurosci2018; 38: 1558–1574.
21.
TotahNKBLogothetisNKEschenkoO. Noradrenergic ensemble-based modulation of cognition over multiple timescales. Brain Res2019; 1709: 50–66.
22.
RodenkirchCLiuYSchriverBJ, et al.Locus coeruleus activation enhances thalamic feature selectivity via norepinephrine regulation of intrathalamic circuit dynamics. Nat Neurosci2019; 22: 120–133.
23.
StrosbergA. Structure, function, and regulation of adrenergic receptors. Protein Sci1993; 2: 1198–1209.
24.
SlaterCWangQ. Alzheimer's disease: an evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. Clin Transl Med2021; 11: e397.
25.
ChalermpalanupapTSchroederJPRorabaughJM, et al.Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. J Neurosci2018; 38: 74–92.
26.
Jacobs HeidiILBecker JohnAKwongK, et al.In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer’s disease pathology and cognitive decline. Sci Transl Med2021; 13: eabj2511.
27.
ManayeKFMoutonPRXuG, et al.Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age (Dordr)2013; 35: 139–147.
28.
GoodmanAMLangnerBMJacksonN, et al.Heightened hippocampal beta-adrenergic receptor function drives synaptic potentiation and supports learning and memory in the TgF344-AD rat model during prodromal Alzheimer's disease. J Neurosci2021; 41: 5747–5761.
29.
TamanoHIshikawaYShioyaA, et al.Adrenergic beta receptor activation reduces amyloid beta(1-42)-mediated intracellular Zn(2+) toxicity in dentate granule cells followed by rescuing impairment of dentate gyrus LTP. Neurotoxicology2020; 79: 177–183.
30.
BrancaCWiselyEVHartmanLK, et al.Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol Aging2014; 35: 2726–2735.
31.
WangDGovindaiahGLiuR, et al.Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J2010; 24: 3511–3521.
32.
LiSJinMZhangD, et al.Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron2013; 77: 929–941.
33.
ChaiGSWangYYYashengA, et al.Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer's disease mice. Neural Regen Res2016; 11: 1617–1624.
34.
ChaiGSWangYYZhuD, et al.Activation of beta(2)-adrenergic receptor promotes dendrite ramification and spine generation in APP/PS1 mice. Neurosci Lett2017; 636: 158–164.
35.
JinMWeiZRamalingamN, et al.Activation of beta(2)-adrenergic receptors prevents AD-type synaptotoxicity via epigenetic mechanisms. Mol Psychiatry2023; 28: 4877–4888.
36.
HuttenDRBosJHJde VosS, et al.Targeting the beta-2-adrenergic receptor and the risk of developing Alzheimer's disease: a retrospective inception cohort study. J Alzheimers Dis2022; 87: 1089–1101.
NiYZhaoXBaoG, et al.Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med2006; 12: 1390–1396.
39.
WuQSunJXSongXH, et al.Blocking beta 2-adrenergic receptor inhibits dendrite ramification in a mouse model of Alzheimer's disease. Neural Regen Res2017; 12: 1499–1506.
40.
ZhangFGannonMChenY, et al.β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade. Sci Transl Med2020; 12: eaay6931.
41.
ZhangFGannonMChenY, et al.The amyloid precursor protein modulates alpha(2A)-adrenergic receptor endocytosis and signaling through disrupting arrestin 3 recruitment. FASEB J2017; 31: 4434–4446.
42.
ChenYPengYCheP, et al.Alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc Natl Acad Sci U S A2014; 111: 17296–17301.
43.
InfantinoRBoccellaSScuteriD, et al.2-pentadecyl-2-oxazoline Prevents cognitive and social behaviour impairments in the amyloid beta-induced Alzheimer-like mice model: bring the alpha2 adrenergic receptor back into play. Biomed Pharmacother2022; 156: 113844.
44.
GibbsMEMakselDGibbsZ, et al.Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist. Neurobiol Aging2010; 31: 614–624.
45.
TournissacMVuTMVrabicN, et al.Repurposing beta-3 adrenergic receptor agonists for Alzheimer's disease: beneficial effects in a mouse model. Alzheimers Res Ther2021; 13: 103.
46.
YuZYYiXWangYR, et al.Inhibiting alpha1-adrenergic receptor signaling pathway ameliorates AD-type pathologies and behavioral deficits in APPswe/PS1 mouse model. J Neurochem2022; 161: 293–307.
47.
SlaterCLiuYWeissE, et al.The neuromodulatory role of the noradrenergic and cholinergic systems and their interplay in cognitive functions: a focused review. Brain Sci2022; 12: 890.
48.
JiangSLiYZhangC, et al.M1 muscarinic acetylcholine receptor in Alzheimer's disease. Neurosci Bull2014; 30: 295–307.
ChenGJXiongZYanZ. Abeta impairs nicotinic regulation of inhibitory synaptic transmission and interneuron excitability in prefrontal cortex. Mol Neurodegener2013; 8: 3.
51.
Santos-TorresJFuenteACriadoJM, et al.Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum. J Neurosci Res2007; 85: 634–648.
52.
DoughertyJJWuJNicholsRA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci2003; 23: 6740–6747.
53.
BorroniVBarrantesFJ. Homomeric and heteromeric α7 nicotinic acetylcholine receptors in health and some central nervous system diseases. Membranes2021; 11: 664.
54.
WangHYLeeDHD'AndreaMR, et al.beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem2000; 275: 5626–5632.
55.
CeconEDamJLukaM, et al.Quantitative assessment of oligomeric amyloid beta peptide binding to alpha7 nicotinic receptor. Br J Pharmacol2019; 176: 3475–3488.
56.
LasalaMFabianiCCorradiJ, et al.Molecular modulation of human alpha7 nicotinic receptor by amyloid-beta peptides. Front Cell Neurosci2019; 13: 37.
57.
SpencerJPWeilAHillK, et al.Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors. Neuroscience2006; 137: 795–805.
58.
MaatukNSamsonAO. Modeling the binding mechanism of Alzheimer's Abeta1-42 to nicotinic acetylcholine receptors based on similarity with snake alpha-neurotoxins. Neurotoxicology2013; 34: 236–242.
59.
AshenafiSFuenteACriadoJM, et al.Beta-Amyloid peptide25-35 depresses excitatory synaptic transmission in the rat basolateral amygdala “in vitro”. Neurobiol Aging2005; 26: 419–428.
ChenLYamadaKNabeshimaT, et al.Alpha7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology2006; 50: 254–268.
63.
HeYXWuMNZhangH, et al.Amyloid beta-protein suppressed nicotinic acetylcholine receptor-mediated currents in acutely isolated rat hippocampal CA1 pyramidal neurons. Synapse2013; 67: 11–20.
64.
HahmETNagarajaRYWaroG, et al.Cholinergic homeostatic synaptic plasticity drives the progression of abeta-induced changes in neural activity. Cell Rep2018; 24: 342–354.
65.
StoiljkovicMKelleyCHajosGP, et al.Hippocampal network dynamics in response to alpha7 nACh receptors activation in amyloid-beta overproducing transgenic mice. Neurobiol Aging2016; 45: 161–168.
66.
JuYAsahiTSawamuraN. Arctic Mutant Abeta40 aggregates on alpha7 nicotinic acetylcholine receptors and inhibits their functions. J Neurochem2014; 131: 667–674.
67.
FonarGPolisBSamsDS, et al.Modified snake alpha-neurotoxin averts beta-amyloid binding to alpha7 nicotinic acetylcholine receptor and reverses cognitive deficits in Alzheimer's disease mice. Mol Neurobiol2021; 58: 2322–2341.
68.
SodermanAMikkelsenJDWestMJ, et al.Activation of nicotinic alpha(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP(swe)/PS1DeltaE9 mice. Neurosci Lett2011; 487: 325–329.
69.
MedeirosRCastelloNAChengD, et al.Alpha7 nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. Am J Pathol2014; 184: 520–529.
70.
NiRMarutleANordbergA. Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain. J Alzheimers Dis2013; 33: 841–851.
71.
SinclairPKabbaniN. Nicotinic receptor components of amyloid beta 42 proteome regulation in human neural cells. PLoS One2022; 17: e0270479.
72.
TropeaMRLi PumaDDMeloneM, et al.Genetic deletion of alpha7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer's disease-like pathology. Prog Neurobiol2021; 206: 102154.
73.
DziewczapolskiGGlogowskiCMMasliahE, et al.Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci2009; 29: 8805–8815.
74.
MorettiMZoliMGeorgeAA, et al.The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Mol Pharmacol2014; 86: 306–317.
75.
WuJLiuQTangP, et al.Heteromeric alpha7beta2 nicotinic acetylcholine receptors in the brain. Trends Pharmacol Sci2016; 37: 562–574.
76.
LiuQHuangYXueF, et al.A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci2009; 29: 918–929.
77.
LiuQHuangYShenJ, et al.Functional alpha7beta2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid beta peptides. BMC Neurosci2012; 13: 155.
78.
GeorgeAAVieiraJMXavier-JacksonC, et al.Implications of oligomeric amyloid-beta (oAbeta(42)) signaling through alpha7beta2-nicotinic acetylcholine receptors (nAChRs) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline. J Neurosci2021; 41: 555–575.
79.
GrupeMGrunnetMBastlundJF, et al.Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Basic Cin Pharmacol Toxicol2015; 116: 187–200.
80.
DineleyKTPandyaAAYakelJL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci2015; 36: 96–108.
81.
WuJKuoYPGeorgeAA, et al.beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem2004; 279: 37842–37851.
82.
SalehiBSestitoSRapposelliS, et al.Epibatidine: a promising natural alkaloid in health. Biomolecules2018; 9: 6.
83.
OliveroGGrilliMChenJ, et al.Effects of soluble beta-amyloid on the release of neurotransmitters from rat brain synaptosomes. Front Aging Neurosci2014; 6: 166.
84.
RobertsJPStokoeSASathlerMF, et al.Selective coactivation of alpha7- and alpha4beta2-nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction. J Biol Chem2021; 296: 100402.
85.
FelderCCBymasterFPWardJ, et al.Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem2000; 43: 4333–4353.
86.
CaccamoAOddoSBillingsLM, et al.M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron2006; 49: 671–682.
87.
GuZZhongPYanZ. Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices. J Biol Chem2003; 278: 17546–17556.
88.
JanickovaHRudajevVZimcikP, et al.Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42). Neuropharmacology2013; 67: 272–283.
89.
MissaleCNashSRRobinsonSW, et al.Dopamine receptors: from structure to function. Physiol Rev1998; 78: 189–225.
90.
HisaharaSShimohamaS. Dopamine receptors and Parkinson’s disease. Int J Med Chem2011; 2011: 403039.
91.
SeemanPNiznikHB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J1990; 4: 2737–2744.
92.
Moreno-CastillaPRodriguez-DuranLFGuzman-RamosK, et al.Dopaminergic neurotransmission dysfunction induced by amyloid-β transforms cortical long-term potentiation into long-term depression and produces memory impairment. Neurobiol Aging2016; 41: 187–199.
93.
KumarUPatelSC. Immunohistochemical localization of dopamine receptor subtypes (D1R–D5R) in Alzheimer's disease brain. Brain Res2007; 1131: 187–196.
94.
KemppainenNLaineMLaaksoM, et al.Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci2003; 18: 149–154.
95.
ChengZ-YXiaQ-PHuY-H, et al.Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice. Int Immunopharmacol2020; 88: 106963.
96.
ZangXChengZ-YSunY, et al.The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ1–42-induced cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry2018; 81: 250–261.
97.
LiuXChengZ-YLiY-F, et al.Dopamine D2 receptor agonist bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation in mice. Eur J Pharmacol2023; 938: 175443.
98.
MartoranaADi LorenzoFEspositoZ, et al.Dopamine D2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology2013; 64: 108–113.
99.
SharpTBarnesNM. Central 5-HT receptors and their function; present and future. Neuropharmacology2020; 177: 108155.
Carhart-HarrisRLNuttDJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol2017; 31: 1091–1120.
102.
EreminDVKondaurovaEMRodnyyAY, et al.Serotonin receptors as a potential target in the treatment of Alzheimer's disease. Biochemistry (Mosc)2023; 88: 2023–2042.
103.
VidalBSebtiJVerdurandM, et al.Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: a post-mortem study with PET radiopharmaceuticals. Neuropharmacology2016; 109: 88–95.
104.
MattssonPCselenyiZAndreeB, et al.Decreased 5-HT(1A) binding in mild Alzheimer's disease-A positron emission tomography study. Synapse2022; 76: e22235.
105.
VerdurandMBerodALe BarsD, et al.Effects of amyloid-beta peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus. Neurobiol Aging2011; 32: 103–114.
106.
TruchotLCostesSNZimmerL, et al.Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology2007; 69: 1012–1017.
107.
VerdurandMChauveauFDaoustA, et al.Differential effects of amyloid-beta 1-40 and 1-42 fibrils on 5-HT1A serotonin receptors in rat brain. Neurobiol Aging2016; 40: 11–21.
108.
AfsharSShahidiSRohaniAH, et al.The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in streptozotocin-induced memory deficits in male rats. Psychopharmacology (Berl)2018; 235: 2809–2822.
109.
AfsharSShahidiSRohaniAH, et al.Protective effects of 5-HT(1A) receptor antagonist and 5-HT(2A) receptor agonist on the biochemical and histological features in a rat model of Alzheimer's disease. J Chem Neuroanat2019; 96: 140–147.
110.
WangMZongHFChangKW, et al.5-HT(1A)R Alleviates Abeta-induced cognitive decline and neuroinflammation through crosstalk with NF-kappaB pathway in mice. Int Immunopharmacol2020; 82: 106354.
111.
MarnerLFrokjaerVGKalbitzerJ, et al.Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging2012; 33: 479–487.
112.
HasselbalchSGMadsenKSvarerC, et al.Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging2008; 29: 1830–1838.
113.
LaiMKTsangSWAlderJT, et al.Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl)2005; 179: 673–677.
114.
ChristensenRMarcussenABWortweinG, et al.Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp Neurol2008; 210: 164–171.
115.
HolmPEttrupAKleinAB, et al.Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice. J Alzheimers Dis2010; 20: 1201–1213.
116.
LuJZhangCLvJ, et al.Antiallergic drug desloratadine as a selective antagonist of 5HT(2A) receptor ameliorates pathology of Alzheimer's disease model mice by improving microglial dysfunction. Aging Cell2021; 20: e13286.
117.
AcquaroneEArgyrousiEKArancioO, et al.The 5HT2b receptor in Alzheimer’s disease: increased levels in patient brains and antagonist attenuation of amyloid and tau induced dysfunction. J Alzheimers Dis2024; 98: 1349–1360.
118.
AnzaloneMKaramSABritingSR, et al.Serotonin-2B receptor (5-HT2BR) expression and binding in the brain of APPswe/PS1dE9 transgenic mice and in Alzheimer’s disease brain tissue. Neurosci Lett2025; 844: 138013.
119.
BarangerKGiannoniPGirardSD, et al.Chronic treatments with a 5-HT(4) receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology2017; 126: 128–141.
120.
QuiedevilleABoulouardMHamidoucheK, et al.Chronic activation of 5-HT4 receptors or blockade of 5-HT6 receptors improve memory performances. Behav Brain Res2015; 293: 10–17.
121.
GiannoniPGavenFde BundelD, et al.Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. Front Aging Neurosci2013; 5: 96.
122.
NirogiRMohammedARShindeAK, et al.Discovery and preclinical characterization of usmarapride (SUVN-D4010): a potent, selective 5-HT(4) receptor partial agonist for the treatment of cognitive deficits associated with Alzheimer's disease. J Med Chem2021; 64: 10641–10665.
123.
FisherJRWallaceCETripoliDL, et al.Redundant Gs-coupled serotonin receptors regulate amyloid-beta metabolism in vivo. Mol Neurodegener2016; 11: 45.
124.
PimenovaAAThathiahADe StrooperB, et al.Regulation of amyloid precursor protein processing by serotonin signaling. PLoS One2014; 9: e87014.
125.
CochetMDonnegerRCassierE, et al.5-HT4 Receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci2013; 4: 130–140.
126.
Hashemi-FirouziNShahidiSSoleimani-AslS, et al.5-Hydroxytryptamine Receptor 6 antagonist, SB258585 exerts neuroprotection in a rat model of streptozotocin-induced Alzheimer's disease. Metab Brain Dis2018; 33: 1243–1253.
127.
IvachtchenkoAVLavrovskyYIvanenkovYA. AVN-211, novel and highly selective 5-HT6 receptor small molecule antagonist, for the treatment of Alzheimer's disease. Mol Pharm2016; 13: 945–963.
128.
ShahidiSHashemi-FirouziNAslSS, et al.Serotonin type 6 receptor antagonist attenuates the impairment of long-term potentiation and memory induced by Abeta. Behav Brain Res2019; 364: 205–212.
129.
HuLWangBZhangY. Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function. Alzheimers Res Ther2017; 9: 76.
130.
RychtykJPartykaAGdula-ArgasinskaJ, et al.5-HT(6) Receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801. Brain Res2019; 1722: 146375.
131.
ShahidiSAslSSKomakiA, et al.The effect of chronic stimulation of serotonin receptor type 7 on recognition, passive avoidance memory, hippocampal long-term potentiation, and neuronal apoptosis in the amyloid beta protein treated rat. Psychopharmacology (Berl)2018; 235: 1513–1525.
132.
Hashemi-FirouziNKomakiASoleimani AslS, et al.The effects of the 5-HT7 receptor on hippocampal long-term potentiation and apoptosis in a rat model of Alzheimer's disease. Brain Res Bull2017; 135: 85–91.
133.
SchoeppDD. Novel functions for subtypes of metabotropic glutamate receptors. Neurochem Int1994; 24: 439–449.
134.
MarcantoniACerulloMSBuxedaP, et al.Amyloid Beta42 oligomers up-regulate the excitatory synapses by potentiating presynaptic release while impairing postsynaptic NMDA receptors. J Physiol2020; 598: 2183–2197.
135.
MullerMKJacobiESakimuraK, et al.NMDA Receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (Abeta) overexpressing mice. Acta Neuropathol Commun2018; 6: 110.
136.
TaniguchiKYamamotoFAmanoA, et al.Amyloid-beta oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: relevance to the synapse pathology of Alzheimer's disease. Neurosci Res2022; 180: 90–98.
137.
OlajideOJChapmanCA. Amyloid-beta (1-42) peptide induces rapid NMDA receptor-dependent alterations at glutamatergic synapses in the entorhinal cortex. Neurobiol Aging2021; 105: 296–309.
138.
KesselsHWNabaviSMalinowR. Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A2013; 110: 4033–4038.
139.
ShankarGMLiSMehtaTH, et al.Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med2008; 14: 837–842.
140.
RaymondCRIrelandDRAbrahamWC. NMDA Receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res2003; 968: 263–272.
141.
KervernMAngeliANicoleO, et al.Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-beta peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis2012; 32: 183–196.
142.
BackMKRuggieriSJacobiE, et al.Amyloid beta-mediated changes in synaptic function and spine number of neocortical neurons depend on NMDA receptors. Int J Mol Sci2021; 22: 6298.
143.
ShankarGMBloodgoodBLTownsendM, et al.Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci2007; 27: 2866–2875.
144.
TackenbergCGrinschglSTrutzelA, et al.NMDA Receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis2013; 4: e608.
145.
SnyderEMNongYAlmeidaCG, et al.Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci2005; 8: 1051–1058.
146.
HoeySEWilliamsRJPerkintonMS. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci2009; 29: 4442–4460.
147.
BordjiKBecerril-OrtegaJNicoleO, et al.Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. J Neurosci2010; 30: 15927–15942.
148.
LesneSAliCGabrielC, et al.NMDA Receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci2005; 25: 9367–9377.
149.
SinnenBLBowenABGibsonES, et al.Local and use-dependent effects of beta-amyloid oligomers on NMDA receptor function revealed by optical quantal analysis. J Neurosci2016; 36: 11532–11543.
150.
AlberdiESanchez-GomezMVCavaliereF, et al.Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium2010; 47: 264–272.
151.
JohnsonJWKotermanskiSE. Mechanism of action of memantine. Curr Opin Pharmacol2006; 6: 61–67.
152.
VaradharajanADavisADGhoshA, et al.Guidelines for pharmacotherapy in Alzheimer’s disease–A primer on FDA-approved drugs. J Neurosci Rural Pract2023; 14: 566.
153.
XiaPChenHSZhangD, et al.Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci2010; 30: 11246–11250.
154.
Martinez-CoriaHGreenKNBillingsLM, et al.Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol2010; 176: 870–880.
155.
DeckerHLoKYUngerSM, et al.Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci2010; 30: 9166–9171.
156.
StaziMWirthsO. Chronic memantine treatment ameliorates behavioral deficits, neuron loss, and impaired neurogenesis in a model of Alzheimer's disease. Mol Neurobiol2021; 58: 204–216.
157.
LeiMXuHLiZ, et al.Soluble Abeta oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. Neurobiol Dis2016; 85: 111–121.
VergesDKRestivoJLGoebelWD, et al.Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci2011; 31: 11328–11337.
160.
LiSJinMKoeglspergerT, et al.Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci2011; 31: 6627–6638.
161.
RammesGHasenjagerASroka-SaidiK, et al.Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology2011; 60: 982–990.
162.
ShemerIHolmgrenCMinR, et al.Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci2006; 23: 2035–2047.
163.
ZhangYGuoOHuoY, et al.Amyloid-beta induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer's disease. J Alzheimers Dis2018; 62: 1789–1801.
164.
AlmeidaCGTampelliniDTakahashiRH, et al.Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis2005; 20: 187–198.
165.
GuZLiuWYanZ. beta-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem2009; 284: 10639–10649.
166.
GuntupalliSJangSEZhuT, et al.Glua1 subunit ubiquitination mediates amyloid-beta-induced loss of surface alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J Biol Chem2017; 292: 8186–8194.
167.
D'AmelioMCavallucciVMiddeiS, et al.Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci2011; 14: 69–76.
168.
WhitcombDJHoggELReganP, et al.Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus. Sci Rep2015; 5: 10934.
169.
BernareggiADuenasZReyes-RuizJM, et al.Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc Natl Acad Sci U S A2007; 104: 2956–2960.
170.
HsiehHBoehmJSatoC, et al.AMPAR Removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron2006; 52: 831–843.
171.
ReindersNRPaoYRennerMC, et al.Amyloid-beta effects on synapses and memory require AMPA receptor subunit GluA3. Proc Natl Acad Sci U S A2016; 113: E6526–E6534.
172.
Fernandez-PerezEJMunozBBascunanDA, et al.Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. Aging Cell2021; 20: e13455.
173.
HettingerJCLeeHBuG, et al.AMPA-ergic regulation of amyloid-beta levels in an Alzheimer's disease mouse model. Mol Neurodegener2018; 13: 22.
174.
PiersTMKimDHKimBC, et al.Translational concepts of mGluR5 in synaptic diseases of the brain. Front Pharmacol2012; 3: 199.
175.
UmJWKaufmanACKostylevM, et al.Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron2013; 79: 887–902.
176.
HuNWNicollAJZhangD, et al.Mglu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun2014; 5: 3374.
177.
HaasLTSalazarSVKostylevMA, et al.Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain2016; 139: 526–546.
178.
Abd-ElrahmanKSAlbakerAde SouzaJM, et al.Abeta oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner. Sci Signal2020; 13: eabd2494.
179.
RennerMLacorPNVelascoPT, et al.Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron2010; 66: 739–754.
180.
WangQWalshDMRowanMJ, et al.Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci2004; 24: 3370–3378.
181.
HamiltonAVasefiMVander TuinC, et al.Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. Cell Rep2016; 15: 1859–1865.
182.
BelloziPMQGomesGFda SilvaMCM, et al.A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology2019; 160: 107785.
183.
EveringtonEAGibbardAGSwinnyJD, et al.Molecular characterization of GABA-A receptor subunit diversity within major peripheral organs and their plasticity in response to early life psychosocial stress. Front Mol Neurosci2018; 11: 18.
184.
WatanabeMMaemuraKKanbaraK, et al.GABA And GABA receptors in the central nervous system and other organs. Int Rev Cytol2002; 213: 1–47.
185.
LimonAReyes-RuizJMMilediR. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci U S A2012; 109: 10071–10076.
186.
LiYZhuKLiN, et al.Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimers Res Ther2021; 13: 114.
187.
KellyLSeifiMMaR, et al.Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer's patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathol Appl Neurobiol2021; 47: 488–505.
188.
Calvo-Flores GuzmanBKimSChawdharyB, et al.Amyloid-beta(1-42) -induced increase in GABAergic tonic conductance in mouse hippocampal CA1 pyramidal cells. Molecules2020; 25: 693.
189.
Nava-MesaMOJiménez-DíazLYajeyaJ, et al.GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Front Cell Neurosci2014; 8: 167.
190.
LeeBYBanJYSeongYH. Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells. Neurosci Res2005; 52: 347–356.
191.
Paula-LimaACDe FeliceFGBrito-MoreiraJ, et al.Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. Neuropharmacology2005; 49: 1140–1148.
192.
VinnakotaCGovindpaniKTateWP, et al.An 5 GABAA receptor inverse agonist, 5IA, attenuates amyloid beta-induced neuronal death in mouse hippocampal cultures. Int J Mol Sci2020; 21: 3284.
193.
SawadaMIchinoseM. Amyloid beta proteins reduce the GABA-induced Cl- current in identified Aplysia neurons. Neurosci Lett1996; 213: 213–215.
194.
YoshiikeYKimuraTYamashitaS, et al.GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One2008; 3: e3029.
195.
SunBHalabiskyBZhouY, et al.Imbalance between GABAergic and glutamatergic transmission impairs adult neurogenesis in an animal model of Alzheimer's disease. Cell Stem Cell2009; 5: 624–633.
196.
PalopJJChinJRobersonED, et al.Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron2007; 55: 697–711.
197.
Paula-LimaACLouzadaPRDe MelloFG, et al.Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved?Neurotox Res2003; 5: 323–327.
Martin-BelmonteAAguadoCAlfaro-RuizR, et al.Density of GABA(B) receptors is reduced in granule cells of the hippocampus in a mouse model of Alzheimer's disease. Int J Mol Sci2020; 21: 2459.
200.
MassoneSVassalloIFiorinoG, et al.17A, A novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis2011; 41: 308–317.
201.
KreisADesloovereJSuelvesN, et al.Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. Sci Rep2021; 11: 17600.
202.
AlmasiAZareiMRaoufiS, et al.Influence of hippocampal GABA(B) receptor inhibition on memory in rats with acute beta-amyloid toxicity. Metab Brain Dis2018; 33: 1859–1867.
203.
RodenkirchCCarmelJBWangQ. Rapid effects of vagus nerve stimulation on sensory processing through activation of neuromodulatory systems. Front Neurosci2022; 16: 922424.
